Health experts are alarmed as Republicans degrade the country’s pivotal HIV programs — and break promises made during Trump’s ...
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...
Irish minister describes AMR as ‘one of the greatest global health challenges of our time’ as the government seeks to ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback